Synlogic, Inc. (0A8U.L)

1,8450 -0,0030 (-0,16%) Alla chiusura: 03:42PM BST

Synlogic, Inc.

301 Binney Street
Suite 402
Cambridge, MA 02142
United States
617 401 9975
https://www.synlogictx.com

Settore/i: 
Settore: 
Impiegati a tempo pieno: 6

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Antoine Awad	Principal Executive Officer	580,33k	N/D	1980
Dr. Timothy K. Lu M.D., Ph.D.	Co-Founder & Member of Scientific Advisory Board	N/D	N/D	1981
Dr. James J. Collins Ph.D.	Co-Founder & Member of Scientific Advisory Board	N/D	N/D	1966
Ms. Mary Beth Dooley	VP, Head of Finance and Principal Financial Officer & Principal Accounting Officer	N/D	N/D	1981
Mr. Brendan St. Amant	General Counsel & Corporate Secretary	N/D	N/D	N/D
Mr. Ajay Munshi	Vice President of Corporate Development	N/D	N/D	N/D
Mr. Adam J. Thomas	Chief People Officer	N/D	N/D	N/D
Dr. Caroline B. Kurtz Ph.D.	Chief Development Officer	N/D	N/D	N/D
Ms. Molly Harper	Chief Business Officer	N/D	N/D	1977
Dr. Neal Sondheimer M.D., Ph.D.	VP & Head of Clinical	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.

Governance aziendale

L'ISS Governance QualityScore di Synlogic, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.